| Attributable mortality of candidemia–Results from the ECMM Candida III multinational European Observational Cohort Study J Salmanton-García, OA Cornely, J Stemler, A Barac, J Steinmann, ... Journal of Infection, 106229, 2024 | | 2024 |
| Immunogenicity, reactogenicity and safety of a second booster with BNT162b2 or full-dose mRNA-1273: a randomised VACCELERATE trial in adults≥ 75 years (EU-COVAT-1-AGED Part B) J Stemler, L Yeghiazaryan, C Stephan, KGI Mohn, AJ Carcas-Sansuan, ... International Journal of Infectious Diseases, 107161, 2024 | | 2024 |
| Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022 J Salmanton-García, F Marchesi, F Farina, B Weinbergerová, F Itri, ... EClinicalMedicine 71, 2024 | 2 | 2024 |
| Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM M Bassetti, DR Giacobbe, C Agvald-Ohman, M Akova, ... Intensive Care Medicine 50 (4), 502-515, 2024 | 12 | 2024 |
| The Cologne ECMM Excellence Center: A Two-Year Analysis of External Consultation Service for Invasive Fungal Infections J Salmanton-García, P Koehler, JH Grothe, SC Mellinghoff, E Sal, ... Mycopathologia 189 (2), 25, 2024 | 1 | 2024 |
| Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP) F Steinbeis, C Thibeault, S Steinbrecher, Y Ahlgrimm, IA Haack, D August, ... Infection 52 (1), 93-104, 2024 | | 2024 |
| Predicting the next pandemic: VACCELERATE ranking of the World Health Organization's Blueprint for Action to Prevent Epidemics J Salmanton-García, P Wipfler, J Leckler, P Nauclér, PW Mallon, ... Travel Medicine and Infectious Disease 57, 102676, 2024 | | 2024 |
| Questioning the 14‐day dogma in candidemia treatment duration J Salmanton‐García, I Reinhold, J Prattes, N Bekaan, P Koehler, ... Mycoses 67 (1), e13672, 2024 | 2 | 2024 |
| 2383. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: a randomised trial in adults≥ 75 years (EU-COVAT-1) from the VACCELERATE … J Salmanton-Garcia, JM Neuhann, J Stemler, A Carcas, J Frías-Iniesta, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 2003, 2023 | | 2023 |
| Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III … M Egger, J Salmanton-García, A Barac, JP Gangneux, H Guegan, ... Mycopathologia 188 (6), 983-994, 2023 | 7 | 2023 |
| Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults≥ 75 years (EU-COVAT-1) JM Neuhann, J Stemler, AJ Carcas, J Frías-Iniesta, M Akova, U Bethe, ... Vaccine 41 (48), 7166-7175, 2023 | 4 | 2023 |
| Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time G Kenny, S O’Reilly, N Wrigley Kelly, R Negi, C Gaillard, D Alalwan, ... Nature Communications 14 (1), 7015, 2023 | 8 | 2023 |
| Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia OA Cornely, H Ostermann, P Koehler, D Teschner, E Limburg, ... Journal of Antimicrobial Chemotherapy 78 (11), 2645-2652, 2023 | 6 | 2023 |
| European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study MC Arendrup, S Arikan-Akdagli, KM Jørgensen, A Barac, J Steinmann, ... Journal of Infection 87 (5), 428-437, 2023 | 33 | 2023 |
| Which trial do we need? Combination treatment of Pneumocystis jirovecii pneumonia in non-HIV infected patients P Koehler, J Prattes, M Simon, L Haensel, M Hellmich, OA Cornely Clinical Microbiology and Infection 29 (10), 1225-1228, 2023 | 9 | 2023 |
| Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry J Salmanton-García, F Marchesi, P Koehler, B Weinbergerová, N Čolović, ... International Journal of Antimicrobial Agents 62 (4), 106952, 2023 | 5 | 2023 |
| A second update on mapping the human genetic architecture of COVID-19 M Kanai, SJ Andrews, M Cordioli, C Stevens, BM Neale, M Daly, A Ganna, ... Nature 621 (7977), E7-E26, 2023 | 27 | 2023 |
| Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG DR Giacobbe, S Dettori, V Di Pilato, E Asperges, L Ball, E Berti, ... Critical Care 27 (1), 323, 2023 | 12 | 2023 |
| P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT J Salmanton-García, F Marchesi, A Glenthøj, YM Bilgin, JVAN Praet, ... HemaSphere 7 (S3), e65137d1, 2023 | | 2023 |
| P586: POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA–CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING C Joisten, C Müller, S Mellinghoff, C Maurer, KA Kreuzer, M Wiesen, ... HemaSphere 7 (S3), e454364d, 2023 | | 2023 |
